Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Palbociclib Receives Breakthrough Designation for Treatment of Breast Cancer

April 10th 2013

The drug palbociclib (formerly known as PD-0332991) has received has received a "breakthrough therapy designation" from the FDA for the treatment of patients with breast cancer.

Dr. Esserman on the I-SPY 2 Trial in Breast Cancer

April 10th 2013

Laura Esserman, MD, MBA, Professor, University of California, San Francisco, comments on the findings from the I-SPY 1 trial and the basis for the I-SPY 2 trial in patients with breast cancer.

Baselga Recaps Research Into Three Breast Cancer Pathways

April 9th 2013

JosÃ© Baselga, MD, PhD, explores the dual inhibition of cell-signaling pathways in breast cancer on several fronts, including new therapies for patients with the HER2-positive subtype and novel ways to target mTOR and the PI3K/Akt/mTOR pathway.

Dr. Borgen Discusses the Patents on BRCA1 and BRCA2

April 8th 2013

Patrick Borgen, MD, chair, Department of Surgery, director, Maimonides Breast Cancer Center, discusses the patents on BRCA1 and BRCA2.

Dr. Carey on Everolimus in Metastatic Breast Cancer

April 5th 2013

Lisa A. Carey, MD, Professor of Medicine, University of North Carolina at Chapel Hill, discusses the use of everolimus in the metastatic and adjuvant settings of breast cancer.

Dr. Sledge Discusses Lasting Issues in Breast Cancer

April 4th 2013

George W. Sledge, Jr, MD, Chief, Division of Oncology, Professor of Medicine, Stanford University School of Medicine, discusses the lasting issues in the treatment of breast cancer.

Dr. Muss on the Treatment Team for Older Cancer Patients

April 3rd 2013

Hyman B. Muss, MD, Professor of Medicine, Director of Geriatric Oncology, Division of Hematology and Oncology, Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill School of Medicine, discusses the need for a team environment when treating an older patient.

Dr. Andre on Research in Metastatic Breast Cancer

April 2nd 2013

Fabrice Andre, MD, PhD, Research Director, Head of INSERM Unit U981, Institut National des Sciences et de la Recherche MÃ©dicale, Associate Professor, Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France, discusses upcoming research in metastatic breast cancer.

Dr. Baselga Discusses PIK3CA Inhibitors in Breast Cancer

March 29th 2013

JosÃ© Baselga, MD, PhD, Physician-in-Chief, Memorial Sloan-Kettering Cancer Center, discusses treatment with PIK3CA inhibitors in patients with breast cancer.

Emanuel Petricoin Discusses Tumor Heterogeneity

March 28th 2013

Emanuel F. Petricoin III, PhD, Co-Director, Center for Applied Proteomics & Molecular Medicine, Professor of Life Sciences, George Mason University, discusses tumor heterogeneity in patients with breast cancer.

Dr. Piccart on Metagene Prognostic Signatures

March 27th 2013

Martine Piccart, MD, PhD, director of medicine at the Jules Bordet Institute in Brussels, Belgium, discusses the development of metagene prognostic signatures for patients with breast cancer.

Dr. Mark Pegram Discusses Earlier Treatment With T-DM1

March 26th 2013

Mark D. Pegram, MD, from the Stanford Cancer Institute, describes research into the antibody-drug conjugate T-DM1, following its FDA approval in February as a treatment for HER2-positive metastatic breast cancer.

Dr. Dixon on the Discrepancy in the Rate of Mastectomies

March 25th 2013

J. Michael Dixon, MBChB, MD, Professor of Surgery, Consultant Surgeon, University of Edinburgh, Clinical Director of the Edinburgh Breast Unit, Western General Hospital, Edinburgh, Scotland, discusses the discrepancy in the rate of mastectomies.

Dr. Sledge on the Quantitative Measurement of Mutations

March 21st 2013

George W. Sledge, Jr, MD, Chief, Division of Oncology, Professor of Medicine, Stanford University School of Medicine, discusses measuring mutations in human cancers quantitatively.

Dr. Caudle Describes the ACOSOG Z1071 Study

March 20th 2013

Abigail S. Caudle, MD, Assistant Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, describes the ACOSOG Z1071 study in breast cancer.

Dr. Borgen on the Decision to Undergo a Mastectomy

March 19th 2013

Patrick Borgen, MD, from the Maimonides Breast Cancer Center, details the factors that go into a patient's decision to undergo a mastectomy.

Dr. von Minckwitz on pCR and Outcomes in Breast Cancer

March 15th 2013

Gunter von Minckwitz, MD, PhD, Chairman, German Breast Group, Professor of Gynecology, University of Frankfurt, Germany, discusses pathologic complete response (pCR) and outcomes.

The 2013 Miami Breast Cancer Conference

March 14th 2013

This year marks the 30th Annual Miami Breast Cancer Conference, a milestone for Daniel A. Osman, MD, and his wife Lois, who together launched the gathering in 1983 with fewer than 100 attendees and a focus on the then relatively new domain of lumpectomies in breast cancer treatment.

Dr. Muss Discusses the Need for Geriatric Assessments

March 14th 2013

Hyman B. Muss, MD, Professor of Medicine, Director of Geriatric Oncology, Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill School of Medicine, on the need for geriatric assessments.

Lymphoseek Approved to Help Detect Lymph Nodes in Breast Cancer and Melanoma

March 13th 2013

The FDA approved the radioactive diagnostic imaging agent technetium Tc 99m tilmanocept (Lymphoseek Injection) to identify lymph nodes for potential removal in patients with breast cancer or melanoma.